MOJO STOCKZ BABY YEA!

[Stockz4O]

"Stocks on the Rise- CXAC, LLSR, MGEN"
1/23/2007

Jan 23, 2007 (M2 PRESSWIRE via COMTEX News Network) --
Today, wallstreetgrapevine.com, named; Cross Atlantic Commodities Inc. (OTC BB: CXAC), Lantis Laser Inc. (Pink Sheets: LLSR), and Med Gen Inc. (OTC BB: MGEN); their "Stocks on the Rise."

Cross Atlantic Commodities Inc. (OTC BB: CXAC, http://www.marketwatch.com/tools/quotes/quotes.asp?symb=cxac)

Cross Atlantic Commodities Announces Exclusive Distribution Agreement

Cross Atlantic Commodities, Inc. , is pleased to announce the signing of an exclusive distribution agreement with a German-based manufacturer of unique ice cream products, Durigon Gelato GmbH. Cross Atlantic is now the sole United States distributor of all Durigon products, which consists of independently unique ice cream items that are specifically suitable for mainstream retailers.

Durigon has been an established family business for more than 30 years, with over 150 employees. Durigon's products are currently widely distributed throughout Europe with sales through major retailers in more than 4,000 stores. The company is excited about the opportunity to sell their products throughout the United States, which has an estimated $20 billion ice cream market. Cross Atlantic will showcase Durigon's line of ice cream products to all major retailers, industry specific wholesalers, along with our current regular distribution networks throughout the United States.

Cross Atlantic views the large but conservative ice cream market as an opportunity to penetrate the industry with unique, innovative products, and capture a market share of this $20 billion industry. "We essentially have taken a proven revenue producing product and enhanced it by creating new flavor variations, along with creative presentation," said Jorge Bravo, V.P business development. Mr. Bravo has 20 years of experience in the ice cream industry and he went on to say, "The products that Durigon manufactures have a natural space in the U.S. marketplace. We have the ability to deliver specialty ice cream products that can retail at average prices to the consumer, while retailers are increasing their margins, and therefore maintaining loyal customers." Cross Atlantic is constantly expanding, and diversifying its business to coincide with various market trends. "We are excited about the addition of Durigon's ice cream products to our expanding Wholesale Foods Division," stated Michael Enemaerke CEO, "and having exclusive U.S. distribution rights leaves our company poised for exponential growth." About Cross Atlantic Commodities, Inc.

Cross Atlantic Commodities, Inc. is a diversified commodity importer and holding company, specializing in the coordination of bringing unique food products from the source to commercial worldwide markets. Cross Atlantic Commodities' offices in New York, Miami, Copenhagen and Kampala provide global reach and focus on product diversification. Cross Atlantic Commodities will, through its wholesale food division, work with major retailers in sourcing and importing unique food items for the U.S. markets. The company also plans to brand and manufacture its own line of commodity products and the company is just announcing its first retail product ready for distribution launched under its own brand name, BlackWhiteCoffee.

For more information on Cross Atlantic Commodities, Inc. or its investment opportunities please visit http://www.crossac.com or contact its corporate headquarters at [phone].

Lantis Laser Inc. (Pink Sheets: LLSR, http://www.marketwatch.com/tools/quotes/quotes.asp?symb=llsr&vc=&dist=dr opmenu)

Lantis Laser Inc. (PINKSHEETS: LLSR). Website: www.lantislaser.com. Optical Coherence Tomography (OCT) is considered the 6th and newest imaging modality for biomedical imaging. Light-based and without emitting radiation, OCT in-the-mouth imaging in dentistry has an unprecedented high resolution of up to 10 times dental x-ray and enables dentists to detect very early stages of oral diseases such as decay and periodontal disease. Early detection allows the dentist to employ non- or minimally invasive treatment to enhance the standard of patient care.

Lantis has the exclusive rights to commercialize the application of OCT in the dental field, under its license Agreements with Lawrence Livermore National Laboratory and LightLab Imaging. OCT, discovered in the early 1990s at MIT, has been very successfully commercialized by Carl Zeiss Meditec in the ophthalmology field. In a press release on November 8th, 2006 they announced the sale of their 6000th OCT Stratus System, initially introduced in 2002. At an approximate retail price of $65,000 per system, this puts sales figures for the OCT Stratus System at almost $400 million. LightLab Imaging is commercializing OCT for cardiovascular imaging with systems currently being sold in Europe, with entry in the near future into the US and Japanese markets.

Lantis' OCT Dental Imaging System(TM), currently in Phase II development, addresses the needs of dentists for an affordable, chairside diagnostic imaging system to provide accurate images that can be viewed on a chairside monitor, saved to the patient file, printed or transmitted for insurance purposes or consultation. Currently, dentists' mainstay in imaging is the x-ray that was introduced in 1885, 121 years ago, and still has many diagnostic shortcomings for the needs of modern dentistry. "An upgrade in dental imaging is long overdue and this is evidenced in current dental literature," said Stan Baron, President and CEO of Lantis.

Lantis is targeting to sell its OCT System through major distributors that have worldwide distribution. Target retail price for the OCT System is under $20,000 which puts it within reach of the majority of dentists. The worldwide potential market is estimated at 200,000 dental offices or $4 billion at retail. Lantis' management is highly confident that a market penetration of 5% can be achieved within 4 years of commencing marketing in the third quarter of 2008. Projected sales, at ex factory price, would amount to nearly $75 million for Lantis over this period, which would lay the foundation for an accelerated market penetration with increasing sales being booked for Lantis in future years to come.

Extensive research of OCT biomedical applications is being undertaken at many sites and the emerging importance of this modality is clearly evidenced by the large and varied research papers to be presented at the Photonics West/BiOS 2007 symposium in San Jose, CA, Jan 20-25th. Numerous research presentations in dentistry are also part of the program. Continuing development of OCT applications includes the areas of cardiology, coronary bypass surgery, gastro-enterology, urology and cancer detection.

Med Gen Inc. (OTC BB: MGEN, http://www.marketwatch.com/tools/quotes/quotes.asp?symb=mgen)

Med Gen Revenues on the Rise

Med Gen Inc. , manufacturers of nationally branded OTC healthier life products, announced a substantial increase in revenues for the first half of January.

In discussions with Analysts that follow Med Gen, Paul Kravitz, Chairman/CEO discussed the Med Gen turnaround, prompting a mid-month national release of the company's revenue. Mr. Kravitz said, "in the month of January thru January 22 2007, the company recorded revenue of $277,000, a 6,000% increase over same month revenue in 2006. This increase follows the reported record revenues reported for November and further validates the year-long marketing efforts that management has put in place. The company's management project substantial improvement in revenues for its second (March) quarter." The company also reported that its newest UnDiet(R) TV commercial will have a medical endorsement and will air in early February. It will become the TV commercial platform for several new products the company is readying for launch.

About Med Gen Inc.

Med Gen Inc., in business since 1996, manufactures and markets specialty products using its proprietary delivery system Spray's the Way ("STW"). It is best known for producing the world's first patented liquid spray snoring relief formula, Snorenz(R). Since its existence, Med Gen has continued to develop its STW technology, introducing Good Nights Sleep(R) and the UnDiet(R) system into its family of brands. While STW technology is mainly used, the company also produces other products that deal with common health issues using other delivery systems. The company markets its products to distributors, major chain and drug stores, direct sales via the company web site and direct to consumer television, radio and print advertising. The company also distributes its brands internationally under various private labels or existing names.

Med Gen Inc. is a fully reporting company whose stock trades on the OTCBB under the symbol "MGEN". For information contact Investor Relations, Paul Kravitz, CEO - 561-750-1100 or www.medgen.com.